The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×3•Originally published 14 April 2026•Updated 15 April 2026•

1 min read

Abbott Laboratories to Appeal $70 Million Verdict in Infant Formula Lawsuit

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Abbott Laboratories plans to appeal a US court ruling awarding $70 million in total damages.

about 2 months ago

Version History

Version 3about 2 months ago

What changed: Updated the story to include Q1 earnings projections, downward analyst revisions, and the slowdown in the Nutrition segment.

Version 2about 2 months ago

What changed: Specified the exact product (Similac Special Care 24), identified the plaintiffs as four mothers, and clarified that the $17 million portion consists of punitive damages.

Version 1about 2 months ago

What changed: Specified the legal grounds (negligence and design defect), disclosed the scale of over 1,700 pending lawsuits, and identified the trial location in Chicago.

Abbott Laboratories is appealing a $70 million verdict over its infant formula products as it prepares to report Q1 earnings on April 16. While earnings per share (EPS) are projected to increase by 5.5% to $1.15, analyst sentiment has softened with downward revisions for both revenue and profit estimates. This caution stems from a visible slowdown in the company's Nutrition segment, which is weighing on overall growth projections. These financial headwinds coincide with significant legal liabilities, as the company faces over 1,700 lawsuits related to its Similac products. Despite maintaining that its products are safe, the combination of legal setbacks and slowing segment growth has intensified investor focus on ABT stock. The upcoming earnings call will be critical for assessing how the company plans to navigate these compounding operational and legal risks.